Recombinant Human KAAG1 Protein，His

KAAG1, or Kynurenine Aminotransferase II, is an enzyme that plays a critical role in the kynurenine pathway, which is vital for tryptophan metabolism and the production of neuroactive metabolites. The study of KAAG1 has garnered significant attention due to its implications in various physiological and pathological processes, including neurodegenerative diseases, psychiatric disorders, and immune responses. Research has shown that dysregulation of the kynurenine pathway is linked to conditions such as depression and Alzheimer's disease, highlighting the importance of KAAG1 as a potential therapeutic target. Furthermore, the enzymatic activity of KAAG1 can influence the levels of neuroprotective and neurotoxic metabolites, thereby affecting neuronal health and function. Investigating the structural and functional properties of recombinant KAAG1 protein allows for a deeper understanding of its biological role and opens avenues for drug development aimed at modulating its activity. In recent studies, researchers have focused on the production of recombinant KAAG1 to explore its biochemical characteristics, assay methods, and potential inhibitors. This research not only contributes to the foundational knowledge of KAAG1 but also paves the way for its application in drug discovery and the development of novel therapeutic strategies for treating disorders associated with altered kynurenine metabolism.